Addressing severe pain AND the risks associated with traditional treatments
Commitment without compromise
At Adneuris Therapeutics, we are focused on solving both sides of the pain-treatment puzzle.
- Driven by a profound commitment to transforming the lives of patients living with pain and addiction
- Guided by science and innovation, our mission is to develop targeted solutions that address unmet medical needs with significant social impact
cebranopadol
A new approach to treating serious pain
Adneuris is advancing a new kind of pain medicine: One designed to bring meaningful relief without the challenges patients and physicians have long faced.
Cebranopadol represents a new class of pain treatment with the potential to deliver what patients and physicians have long been waiting for: Strong pain relief with an improved safety profile.
At Adneuris, we are reimagining how pain can be treated with our investigational therapy, cebranopadol. We recognize that pain is highly personal and can have lasting effects, which is why effective pain treatment requires different options for different needs, not a one-size-fits-all solution.
The innovation gap in acute pain has left patients and physicians with limited choices for too long. That’s why Adneuris has developed a first-of-its-kind therapeutic that takes a novel approach of activating both Nociception/Orphanin FQ Peptide (NOP) and µ (MOP) receptors to modulate pain.
- As a dual-NOP/MOP receptor (dual-NMR) agonist, cebranopadol engages the body’s NOP pathway to enhance pain relief while reducing adverse effects like respiratory depression, dependence, and abuse potential.
- Opioids bind to the MOP receptor and create an imbalance in the body that leads to euphoria and dependence, simultaneously engaging the NOP receptor better controls those potential side effects.
How do dual-NMR agonists differ from preferential MOP agonists?
Data demonstrate that novel Dual-NMR agonists may provide significant benefits over preferential MOP agonists offering hope for patients with serious pain.
Reference:
- Singla N, Minkowitz H, Vaughn B, Grieco J, Lesnick M, Hackworth J. Results of a randomized, placebo-controlled, Phase 3 trial of cebranopadol for the treatment of acute pain after abdominoplasty. Presented at: The American Society of Regional Anesthesia (ASRA); May 2025.
*Based on the results from two phase three trials **As demonstrated by the results from two human abuse potential (HAP) studies
